Wound Management News

Vibrio cases and deaths in Florida spiked last year after Hurricane Ian, lending credence to concerns that larger, longer, warmer tropical storms may increase the risk for viral infections, according to a study.

Pain as a patient-reported outcome measure during the treatment of pyoderma gangrenosum may indicate whether a patient is responding to treatment, according to a research letter published in JAMA Dermatology.

Results from DETECT, the phase 3 study that supported the FDA approval of NexoBrid for the treatment of severe thermal burns, was recently published in the Journal of Burn Care & Research, Vericel announced in a release.

On Sept. 1, the CDC issued a health advisory concerning an increased rate of infections in the United States of a flesh-eating bacterium called Vibrio vulnificus.

In this Healio video exclusive, George Martin, MD, discusses highlights from Maui Derm NP+PA, including a new wound healing matrix, which he said improves healing and reduces infection rates.

Diacerein 1% ointment was comparable to vehicle in study endpoints but did outperform vehicle when stratified by disease severity in the treatment of patients with epidermolysis bullosa simplex, according to a study.

The FDA has approved Avita Medical’s premarket approval supplement for the use of its Recell System for the treatment of full-thickness skin defects, according to a press release.

The VeriCyn Wound Wash medical device by Armis Biopharma has received 510(k) clearance from the FDA for use in cleansing wounds of debris, according to a company press release.

Considering the unique characteristics of different skin substitutes will provide improved wound care management that meets patient needs, according to a study.

The FDA has approved Vyjuvek (beremagene geperpavec-svdt), an investigational non-invasive, topical, redosable gene therapy for the treatment of dystrophic epidermolysis bullosa, Krystal Biotech announced in a press release.